US FDA Patient Affairs Office Could Accelerate Involvement With 'Central Entry Point'
FDA floats idea of central office to coordinate patient engagement for symbolic as well as practical reasons.
You may also be interested in...
The agency's principle deputy commissioner says it's creating a patient affairs staff, but will not undergo a reorganization.
Rachel Sherman says agency is creating patient affairs staff, but will not undergo reorganization to create an official office.
New office will develop agency-wide patient engagement policy and serve as entry point for patient groups new to FDA, but will not interfere with existing relationships between advocates and the drugs and biologics centers, FDA Commissioner Gottlieb says.